To include your compound in the COVID-19 Resource Center, submit it here.

Benepali etanercept less immunogenic than reference product in Phase III

A research letter published in the British Journal of Dermatology reported that Benepali etanercept (SB4), a biosimilar of Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN), was less immunogenic than its reference product

Read the full 313 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE